<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360579</url>
  </required_header>
  <id_info>
    <org_study_id>C-144-01</org_study_id>
    <nct_id>NCT02360579</nct_id>
  </id_info>
  <brief_title>Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma</brief_title>
  <acronym>LN-144</acronym>
  <official_title>A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iovance Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iovance Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via
      infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative
      lymphodepletion (NMA LD) preconditioning regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lifileucel is an autologous adoptive cell transfer therapy that utilizes a TIL manufacturing
      process, as originally developed by the NCI, for the treatment of patients with metastatic
      melanoma. The adoptive cell transfer therapy used in this study involves patients receiving a
      lymphocyte depleting preconditioning regimen, prior to infusion of autologous TIL, followed
      by the administration of a regimen of IL-2.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Assessment for Objective Response Rate</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 54 months</time_frame>
    <description>Evaluate the efficacy of LN-144 in patients with unresectable or metastatic melanoma using the objective response rate (ORR), as assessed by the Blinded Independent Review Committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Duration of Response</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 54 months</time_frame>
    <description>Evaluate the efficacy endpoints of duration of response (DOR) by the BIRC and by the investigator per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Disease Control Rate</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 54 months</time_frame>
    <description>Evaluate the efficacy endpoints of disease control rate (DCR) as assessed by the BIRC and by the investigator per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Progression-Free Survival</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 54 months</time_frame>
    <description>Evaluate the efficacy endpoints of progression-free survival (PFS) as assessed by the BIRC and by the investigator per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Until death or up to 60 months</time_frame>
    <description>Evaluate overall survival (OS) and objective response rate (ORR) by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Maximum 60 months</time_frame>
    <description>Incidence rate of treatment-emergent adverse events (AEs) and serious AEs by severity and relationship to Lifileucel (LN-144).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lifileucel</intervention_name>
    <description>A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>LN - 144</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following inclusion criteria to be eligible for participation
        in the study:

        Criteria for Inclusion:

          1. Patients with unresectable or metastatic melanoma (Stage IIIc or Stage IV)

          2. Patients must have progressed following ≥ one prior systemic therapy including a
             programmed cell death protein-1 (PD-1) blocking antibody; and if proto-oncogene B-Raf
             (BRAF) V600 mutation-positive, a BRAF inhibitor or BRAF inhibitor in combination with
             mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor

          3. At least one measurable target lesion, as defined by RECIST v1.1

               -  Lesions in previously irradiated areas (or other local therapy) should not be
                  selected as target lesions, unless treatment was ≥ 3 months prior to Screening,
                  and there has been demonstrated disease progression in that particular lesion

          4. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm
             in diameter post-resection to generate TIL; surgical removal with minimal morbidity
             (defined as any procedure for which expected hospitalization is ≤ 3 days)

          5. Patients must be ≥ 18 years of age at the time of consent. Enrollment of patients &gt; 70
             years of age may be allowed after consultation with the Medical Monitor

          6. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0 or 1 and an estimated life expectancy of ≥ 3 months

          7. In the opinion of the Investigator, patients must be able to complete all
             study-required procedures

          8. Patients must have the following hematologic parameters:

               -  Absolute neutrophil count (ANC) ≥ 1000/mm3

               -  Hemoglobin (Hb) ≥ 9.0 g/dL

               -  Platelet ≥ 100,000/mm3

          9. Patients must have adequate organ function:

               -  Serum alanine transaminase (ALT)/serum glutamic-pyruvic transaminase (SGPT) and
                  aspartate transaminase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) ≤ 3
                  times the upper limit of normal (ULN); patients with liver metastasis ≤ 5 times
                  ULN

               -  Estimated creatinine clearance (eCrCl) ≥ 40 mL/min using the Cockcroft-Gault
                  formula

               -  Total bilirubin ≤ 2 mg/dL

               -  Patients with Gilbert's syndrome must have a total bilirubin ≤ 3 mg/dL

         10. Patients must have recovered from all prior therapy-related adverse events (AEs) to ≤
             Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] v4.03), except for
             alopecia or vitiligo, prior to Enrollment (tumor resection)

               -  Patients with documented ≥ Grade 2 diarrhea or colitis as a result of previous
                  treatment with immune checkpoint inhibitor(s) must have been asymptomatic for at
                  least 6 months and/or had a normal colonoscopy post-immune checkpoint inhibitor
                  treatment, by visual assessment, prior to tumor resection

         11. Patients must have a washout period ≥ 28 days from prior anticancer therapy(ies) to
             the start of the planned NMA-LD preconditioning regimen:

               -  Targeted therapy: MEK/BRAF or other targeted agent

               -  Chemotherapy

               -  Immunotherapy: anti-cytotoxic T lymphocyte-associated antigen 4
                  (CTLA-4)/anti-PD-1, other monoclonal antibody (mAb), or vaccine

               -  Palliative radiation therapy is permitted so long as it does not involve lesions
                  being selected for TIL, or as target or non-target lesions. Washout is not
                  required if all related toxicities have resolved to ≤ Grade 1 as per CTCAE v4.03

         12. Patients of childbearing potential or their partners of childbearing potential must be
             willing to take the appropriate precaution to avoid pregnancy or fathering a child for
             the duration of the study and practice an approved, highly effective method of birth
             control during treatment and for 12 months after receiving the last protocol-related
             therapy

               -  Approved methods of birth control are as follows:

               -  Combined (estrogen and progesterone containing) hormonal birth control associated
                  with inhibition of ovulation: oral, intravaginal, transdermal

               -  Progesterone-only hormonal birth control associated with inhibition of ovulation:
                  oral, injectable, implantable

               -  Intrauterine device (IUD)

               -  Intrauterine hormone-releasing system (IUS)

               -  Bilateral tubal occlusion

               -  Vasectomized partner

               -  True sexual abstinence when this is in line with the preferred and usual
                  lifestyle of the patient. Periodic abstinence (eg, calendar ovulation,
                  symptothermal, post-ovulation methods) is not acceptable

         13. Patients (or legally authorized representative) must have the ability to understand
             the requirements of the study, have provided written informed consent as evidenced by
             signature on an ICF approved by an Institutional Review Board/Independent Ethics
             Committee (IRB/IEC), and agree to abide by the study restrictions and return to the
             site for the required assessments, including the OS Follow-up Period

         14. Patients have provided written authorization for use and disclosure of protected
             health information

        Criteria for Exclusion:

        Patients who meet any of the following criteria are not eligible for participation in this
        study:

          1. Patients who have been shown to be BRAF mutation positive (V600), but have not
             received prior systemic therapy with a BRAF inhibitor alone or a BRAF inhibitor in
             combination with a MEK inhibitor

          2. Patients who have received an organ allograft or prior cell transfer therapy

          3. Patients with melanoma of uveal/ocular origin

          4. Patients who have a history of hypersensitivity to any component or excipient of
             LN-144 or other study drugs:

               -  NMA-LD preconditioning regimen (cyclophosphamide, mesna, and fludarabine)

               -  Antibiotics (ABX) of the aminoglycoside group (ie, streptomycin, gentamicin);
                  except those who are skin-test negative for gentamicin hypersensitivity

               -  Any component of the LN-144 infusion product formulation including dimethyl
                  sulfoxide (DMSO), human serum albumin (HSA), IL-2, and dextran-40

          5. Patients with symptomatic and/or untreated brain metastases (of any size and any
             number)

               -  Patients with definitively treated brain metastases may be considered for
                  Enrollment, and must be stable for ≥ 14 days prior to beginning the NMA LD
                  preconditioning regimen

          6. Patients who are on chronic systemic steroid therapy for any reason

          7. Patients who have active medical illness(es) that would pose increased risk for study
             participation, including: active systemic infections requiring systemic ABX,
             coagulation disorders, or other active major medical illnesses of the cardiovascular,
             respiratory, or immune system

          8. Patients who have any form of primary immunodeficiency (such as severe combined
             immunodeficiency disease [SCID] and acquired immunodeficiency syndrome [AIDS])

          9. Patients who have a left ventricular ejection fraction (LVEF) &lt; 45% or New York Heart
             Association (NYHA) functional classification &gt; Class 1

               -  Patients ≥ 60 years of age and who have a history of ischemic heart disease,
                  chest pain, or clinically significant atrial and/or ventricular arrhythmias must
                  have a cardiac stress test. Patients with any irreversible wall movement
                  abnormalities are excluded

         10. Patients who have a documented forced expiratory volume in 1 second (FEV1) of ≤ 60%

         11. Patients who have had another primary malignancy within the previous 3 years (with the
             exception of carcinoma in situ of the breast, cervix, or bladder; localized prostate
             cancer; and non-melanoma skin cancer that has been adequately treated)

         12. Patients who have received a live or attenuated vaccine within 28 days of beginning
             the NMA-LD preconditioning regimen

         13. Patients who are pregnant or breastfeeding

         14. Patients whose cancer requires immediate attention or who would otherwise suffer a
             disadvantage by participating in this trial

         15. Patients protected by the following constraints:

               -  Hospitalized persons without consent or persons deprived of liberty because of a
                  judiciary or administrative decision

               -  Adult persons with a legal protection measure or persons who cannot express their
                  consent

               -  Patients in emergency situations who cannot consent to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iovance Biotherapeutics Medical Monitor</last_name>
    <role>Study Chair</role>
    <affiliation>Iovance Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology and Hematology Care Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus</name>
      <address>
        <city>Villejuif Cedex</city>
        <state>Ile-de-france</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges cedex</city>
        <state>Limousin</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-alpes</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Rhone-alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen (UKT) - Suedwestdeutschen Tumorzentrum - Zentrum für Neuroonkologie</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein - Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli-cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HM Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirónsalud Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28233</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Hospital General Universitari de València</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute London</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Adoptive Cell Transfer</keyword>
  <keyword>Autologous Adoptive Cell Therapy</keyword>
  <keyword>Cellular Immuno-therapy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Tumor Infiltrating Lymphocytes</keyword>
  <keyword>TIL</keyword>
  <keyword>LN-144</keyword>
  <keyword>IL-2</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Lifileucel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

